People Suffering from Dry Eye Conditions Gets Relief thru Antibacterial Manuka Eye Drops [Interview][Transcript]

Guest: Anthony Moloney

Presenter: Tabetha Moreto

Guest Bio: Anthony Moloney is the CEO and founder of Melcare, an early stage biomedical company commercialising therapeutic products into a global market for eye, wound, skin and ENT care. Anthony has been the commercial partner for clinical trials in the UK, Germany and Australia investigating wound care and dry eye disease. He innovated the marketing of medical honey products in a global market as both a drug and medical device and was founder and CEO of now US-based Medihoney, which was awarded the 2008 Optus Platinum Award for Outstanding Business Contribution to Brisbane and IBM Award for Business Innovation. Anthony has an undergraduate Degree in Applied Science and Post-Graduate Master’s Degree in Technology and Engineering Management.

Segment overview: In today’s Health Supplier Segment, we are joined by Melcare Biomedical CEO Anthony Moloney here to discuss the results of research undertaken by the Queensland University of Technology into the use of its Optimel™ Manuka honey product range for the treatment of Meibomian Gland Dysfunction (MGD) induced dry eye and related dry eye conditions. Melcare Biomedical is a Queensland-based TGA licensed Medical Device manufacturer that offer therapeutic products for skin, wound and eye care using standardised medical honeys for a global market. Most of their ingredients are plant derived and their honey is sourced from the leptospermum (tea tree) plant growing in forest locations.